Why a blood test does not show PMDD
In PMDD, hormone levels in the blood are usually the same as in people without PMDD. Research suggests the brain responds differently to normal shifts in progesterone and allopregnanolone in the luteal phase. That is why no blood test shows PMDD. The pattern becomes visible when symptoms are recorded daily for at least two cycles.
What a blood test can and cannot show
A clinician can order blood tests to rule out other causes, such as a thyroid that is too fast or too slow. That belongs in a careful assessment. The result does not show PMDD itself.
Researchers do not find a characteristic high or low luteal level of progesterone or allopregnanolone that separates PMDD from people without these symptoms. Peripheral levels are not a useful biomarker (Bixo, Stiernman and Bäckström, 2025).
What changes in the luteal phase
After ovulation the corpus luteum makes progesterone. Some of it is converted into allopregnanolone, which acts on the GABA-A receptor, a brain system involved in calm and alertness. The level rises and falls with progesterone, then drops when menstruation starts. Read more on the luteal phase.
In most people, higher concentrations of allopregnanolone are calming. In a smaller group, a lower concentration can go together with restlessness or irritability. A 2025 review links that pattern to PMDD: symptoms follow these shifts in people who are sensitive to them (Bixo et al., 2025).
What studies show when ovulation is suppressed
In a 1998 study, severe premenstrual symptoms stopped when ovulation was suppressed with medication. When estradiol or progesterone was added back, the symptoms returned. In women without those symptoms, the same thing did not happen in the same way (Schmidt et al., 1998). The paper uses the term premenstrual syndrome, which was the name then used for these severe symptoms.
The review by Bixo et al. (2025) places this kind of finding with PMDD. The symptoms fit a sensitivity to normal hormone changes. An abnormal blood value is not required.
Why two cycles of records show the pattern
Guidelines ask for symptoms to be recorded prospectively for at least two cycles before a diagnosis is made. Describing what you remember afterwards is too unreliable for that. This is in the RCOG guideline (Green-top 48), the ISPMD auditable standards (2016), the ACOG guideline from 2023, and the ICD-11 definition, code GA34.41.
DSM-5 asks for the same pattern: symptoms in the week before menstruation, minimal or absent in the week after, with clear distress or impairment, confirmed over at least two cycles. The tool used most often for this is daily DRSP records. The app makes the pattern visible. The app does not make a diagnosis.
What the days after menstruation tell you
In PMDD, symptoms should be minimal or absent in the week after menstruation starts. That is the contrast with the luteal phase. Many people notice it in the follicular phase: the heavy days ease, and the days after feel clearer.
If symptoms stay high throughout the cycle and only get worse before menstruation, an underlying condition fits better. The ACOG guideline (2023) states that distinction. On this site that pattern is called PME. Background is on what PMDD is.
How common this is
A 2024 meta-analysis looked at 44 studies with 50,659 participants (Reilly et al., 2024). With a confirmed diagnosis, meaning prospective records, the pooled prevalence was 3.2% (95% confidence interval 1.7–5.9%). In community samples with that confirmed diagnosis it was 1.6% (1.0–2.5%). With a provisional estimate, without two cycles of records, it was 7.7% (5.3–11.0%).
The figure of 3–8% that is often quoted sits across those ranges. Questionnaires that rely on memory count more people than studies that confirm the pattern over two cycles. The older figure is a mix of two ways of counting.
Which guideline applies where
In the Netherlands, the NVOG wrote a guideline on premenstrual syndrome in 2011. It recommends the ISPMD criteria and a calendar, and it was based on the 2007 RCOG guideline. The current international documents are newer: ACOG Clinical Practice Guideline No. 7 (December 2023) and RCOG Green-top Guideline No. 48 (2016, published in 2017). RCOG reviewed the text in May 2023 and an update is in development. NICE Clinical Knowledge Summaries draws on those sources.
Those guidelines also discuss treatment, including SSRIs, some hormonal contraceptives and cognitive behavioural therapy. Which option fits, and at what dose, is a decision with a clinician. A plain-language overview is on treatment. This page stays with the mechanism and with how the pattern is recognised.
More in this section
The same sources are set out on separate pages: how common it is, two cycles, what guidelines say about treatment, and PME and PMDD in research.
Sources
- Bixo M, Stiernman L, Bäckström T. Neurosteroids and premenstrual dysphoric disorder. The British Journal of Psychiatry. 2025. doi.org/10.1192/bjp.2025.103
- Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine. 1998;338(4):209–216. doi.org/10.1056/NEJM199801223380401
- Reilly TJ, Patel S, Unachukwu IC, et al. The prevalence of premenstrual dysphoric disorder: systematic review and meta-analysis. Journal of Affective Disorders. 2024. pubmed.ncbi.nlm.nih.gov/38199397/
- American College of Obstetricians and Gynecologists. Management of premenstrual disorders. Clinical Practice Guideline No. 7. Obstetrics & Gynecology. 2023;142(6):1516–1533. www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/12/management-of-premenstrual-disorders
- Royal College of Obstetricians and Gynaecologists. Management of Premenstrual Syndrome. Green-top Guideline No. 48. BJOG. 2017;124(3):e73–e105. www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/premenstrual-syndrome-management-green-top-guideline-no-48/
- Ismaili E, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Archives of Women’s Mental Health. 2016. doi.org/10.1007/s00737-016-0631-7
- National Institute for Health and Care Excellence. Clinical Knowledge Summaries: Premenstrual syndrome, supporting evidence. Based on RCOG, ISPMD, ACOG 2023 and BMJ Best Practice 2024. cks.nice.org.uk/topics/premenstrual-syndrome/supporting-evidence/
- World Health Organization. ICD-11 for Mortality and Morbidity Statistics. GA34.41 Premenstrual dysphoric disorder. icd.who.int/browse/2025-01/mms/en#1526774088
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). 2013. Premenstrual dysphoric disorder. www.psychiatry.org/psychiatrists/practice/dsm
- Nederlandse Vereniging voor Obstetrie en Gynaecologie. Richtlijn Premenstrueel syndroom. Utrecht: NVOG; 2011. www.nvog.nl/wp-content/uploads/2020/06/Richtlijn-Premenstrueel-Syndroom.pdf
This page summarises published research and guidelines. It is not medical advice and not a clinical guideline. The app does not diagnose.
PMDD Tracker is not a medical device and does not replace professional advice. The cyclic overview is a tool for pattern recognition, not a medical judgement. Always see a healthcare provider for professional advice. Medical disclaimer.
Frequently asked questions
- Can a blood test show PMDD?
- No. A blood test can rule out other causes, such as a thyroid problem. PMDD shows up in the pattern of symptoms over at least two cycles, not in a hormone level.
- Are my hormones too high or too low?
- Research has not found a characteristic high or low level that separates PMDD from people without it. The explanation that fits best is a different brain response to normal fluctuations.
- What is allopregnanolone?
- Allopregnanolone is made from progesterone. It acts on the GABA-A receptor. Its level rises and falls with progesterone in the luteal phase.
- Why do I need at least two cycles?
- Because memory of symptoms is unreliable. ICD-11, DSM-5, RCOG, ISPMD and ACOG ask for a prospective diary over at least two cycles. The practical side is on daily DRSP records.
Record two cycles and bring them with you
Filling in the DRSP each day makes the pattern visible for you and for a clinician. The app does not diagnose.
In your language. No ads. Privacy first.
